predicting response to car-t therapy with multi-omic approaches
Published 1 year ago • 37 plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
1:35
patient responses to car-t therapy and factors that may influence these responses
-
2:06
subanalysis of the karmma trial: predicting complete response to car-t in multiple myeloma
-
2:23
an update on car-t therapy in aml: challenges & emerging strategies
-
2:44
do biomarkers exist for predicting response to car t-cell therapy?
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
3:27
using ai to predict patient response to car-t cell therapy: analysis of the juliet trial
-
1:53
the impact of t-cell fitness on patient response to car-t therapy
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
2:08
value of mrd status one month after car-t therapy in patients with multiple myeloma
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
2:49
novel strategies to optimize car-t therapy in myeloma
-
4:16
the challenges with car t-cell therapy for t-all and the progress made to overcome these challenges
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
1:38
challenges of car-t therapy in the real-world setting
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
3:49
strategies to improve cost & access to car-t therapy
-
3:53
using mrd status as a metric of car-t efficacy in patients with multiple myeloma